RECEPTOPHARM SIGNS LETTER OF INTENT TO BE AQUIRED BY NUTRA PHARMA CORPORATION

June 19, 2006

Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has announced that ReceptoPharm has signed a letter of intent to be fully acquired by Nutra Pharma Corp.
Genetic Engineering News

KEYWORDS FDAnews Drug Daily Bulletin

FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

RECEPTOPHARM SIGNS LETTER OF INTENT TO BE AQUIRED BY NUTRA PHARMA CORPORATION

Upcoming Events

Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

FDA Ad and Promo Enforcement Trends: Past, Present and Future

EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

Medical Device Cybersecurity: Understand the Latest Developments

Pharmaceutical Process Validation: Best Practices for Success

Featured Products

FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements